Seda Pharmaceutical Development Services

www.sedapds.com/ www.linkedin.com/company/9470766/

Seda Pharmaceutical Development Services provides integrated Pharmaceutical Development and Clinical Pharmacology services to the Biotech sector. We enable rapid and efficient development of optimal medicinal products, from conventional to complex, through pragmatic and coherent scientific excellence. Seda was founded in 2015, and has since demonstrated exceptional growth and expansion in our capabilities which include consultancy, laboratory, and pharmacokinetic modelling services. We provide clients with the experience and expertise found in the development functions of major pharmaceutical companies but with the speed and flexibility required by fast-moving Biotechs. Headquartered in Greater Manchester, UK, our bespoke laboratory and office complex is well equipped for the rapid design, development and evaluation of prototype formulation options, from pre-formulation services to the development of preclinical and clinical formulations. Enhancing the value proposition of our clients is our contribution to bringing new, innovative therapies to patients rapidly and successfully.

Unique integration of clinical pharmacology and pharmaceutical development supports drug product design alongside optimal clinical performance and manufacturability. Our expertise includes oral, injectable and targeted drug delivery systems for synthetic small molecules and complex medicines, from the discovery phase, through first-in-human studies and onwards to product approval.

Paul Dickinson Chief Scientific Officer and Co-Founder

+44 754 048 8390 kati.dematas@sedapds.com

Marcel De Matas Chief Technical Officer and Co-Founder

+44 770 242 3406 marcel.dematas@sedapds.com www.touchlight.com www.linkedin.com/company/touchlight-ltd/

Touchlight is a privately-owned CDMO based in London, UK, focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.

Touchlight’s proprietary doggybone DNA is a linear, double-stranded, covalently closed DNA vector, produced through an enzymatic manufacturing process. It can incorporate genes from 500bp to 20kb making it very flexible to support a range of genetic medicines including mRNA, DNA vaccines and viral vectors.

Karen Fallen Chief Executive Officer

+44 771 364 3928 karen.fallen@touchlight.com

Tori Ondo

Sales Manager

+1 858 344 2223 tori.ondo@touchlight.com